See the DrugPatentWatch profile for omnitrope
Is Omnitrope Approved for Adult Growth Hormone Deficiency?
Yes, Omnitrope (somatropin) is FDA-approved for replacement therapy in adults with growth hormone deficiency (GHD), either alone or with multiple hormone deficiencies from pituitary or hypothalamic disease.[1] Diagnosis requires confirmed GHD via stimulation tests, and treatment starts at 0.2–0.3 mg/day, adjusted by IGF-1 levels and side effects.
How Is It Used in Adults?
Adults receive subcutaneous injections, typically nightly, with doses titrated up to 1 mg/day based on response. Therapy aims to normalize IGF-1 without exceeding normal ranges, monitored every 1–2 months initially.[1] It's not for idiopathic GHD or athletic enhancement.
What Are Common Side Effects in Adult Patients?
Patients report fluid retention (edema), joint/muscle pain, carpal tunnel syndrome, and insulin resistance. Rare risks include glucose intolerance, hypertension, and intracranial hypertension. Long-term use raises concerns for malignancy in predisposed individuals; regular cancer screening is advised.[1]
How Does Diagnosis Work Before Starting Omnitrope?
GHD confirmation needs two stimulation tests (e.g., insulin tolerance or glucagon) showing peak GH below 5 ng/mL, plus low IGF-1. MRI assesses pituitary pathology. Untreated adults risk fatigue, reduced muscle mass, osteoporosis, and cardiovascular issues.[2]
Can It Be Used Off-Label or in Other Conditions?
Omnitrope is approved only for pediatric GHD, Turner syndrome, Prader-Willi, chronic kidney disease (kids), and adult GHD/SGA in adults. Off-label uses like anti-aging or obesity lack evidence and aren't recommended.[1]
Who Makes Omnitrope and What's the Patent Status?
Sandoz (Novartis) manufactures Omnitrope, the first FDA-approved somatropin biosimilar to Genotropin. Key U.S. patents expired around 2014–2016, enabling biosimilars; check DrugPatentWatch.com for latest expirations and challenges.[3]
[1] Omnitrope Prescribing Information, Sandoz Inc., 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021426s038lbl.pdf
[2] Endocrine Society Guidelines on GHD, 2019. https://academic.oup.com/jcem/article/104/9/3593/5487915
[3] DrugPatentWatch.com, Omnitrope Patent Data. https://www.drugpatentwatch.com/p/tradename/OMNITROPE